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Abstract
Background: The aim of this study was to describe the patterns of cannabis use and the associated benefits reported by
patients with fibromyalgia (FM) who were consumers of this drug. In addition, the quality of life of FM patients who
consumed cannabis was compared with FM subjects who were not cannabis users.
Methods: Information on medicinal cannabis use was recorded on a specific questionnaire as well as perceived benefits of
cannabis on a range of symptoms using standard 100-mm visual analogue scales (VAS). Cannabis users and non-users
completed the Fibromyalgia Impact Questionnaire (FIQ), the Pittsburgh Sleep Quality Index (PSQI) and the Short Form 36
Health Survey (SF-36).
Results: Twenty-eight FM patients who were cannabis users and 28 non-users were included in the study. Demographics
and clinical variables were similar in both groups. Cannabis users referred different duration of drug consumption; the route
of administration was smoking (54%), oral (46%) and combined (43%). The amount and frequency of cannabis use were also
different among patients. After 2 hours of cannabis use, VAS scores showed a statistically significant (p,0.001) reduction of
pain and stiffness, enhancement of relaxation, and an increase in somnolence and feeling of well being. The mental health
component summary score of the SF-36 was significantly higher (p,0.05) in cannabis users than in non-users. No significant
differences were found in the other SF-36 domains, in the FIQ and the PSQI.
Conclusions: The use of cannabis was associated with beneficial effects on some FM symptoms. Further studies on the
usefulness of cannabinoids in FM patients as well as cannabinoid system involvement in the pathophysiology of this
condition are warranted.
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Introduction
The main complaint of patients with fibromyalgia (FM) is
chronic generalized pain, although many patients suffer from
concomitant symptoms, such as tiredness, morning stiffness, sleep
and affective disturbances [1]. The pathophysiology of the
disorder is poorly understood. Several mechanisms have been
suggested including central sensitization, suppression of descend-
ing inhibitory pathways, excessive activity of glial cells, and
abnormalities of neurotransmitter release [2]. In addition, blunting
of the hypothalamic-pituitary-adrenal-axis (HPA-axis) and in-
creased autonomic nervous system responsiveness have been
consistently reported in FM patients. Emerging clues suggest that
such dysfunction of the stress response system may be crucial in
the onset of the symptoms of FM [3]. Treatment is based on the
symptomatic relief of symptoms but usually modest results are
obtained. The overall patient’s satisfaction and the health-related
quality of life are consistently poor.
Potential therapeutic uses of cannabis in different types of
pain are currently extensively investigated. Data from clinical
trials with synthetic and plant-based cannabinoids provide a
promising approach for the management of chronic neuropathic
pain of different origins [4]. Additionally, a large body of
evidence currently supports the presence of cannabinoid
receptors and ligands, thus an endocannabinoid neuromodula-
tory system appears to be involved in multiple physiological
functions [5].
There is little clinical information on the effectiveness of
cannabinoids in the amelioration of FM symptoms. Three clinical
trials have suggested the possible benefit of cannabinoid in the
management of FM [6–8]. Furthermore, a clinical endocannabi-
noid deficiency (CECD) has been hypothesized to underlie the
pathophysiology of fibromyalgia, but a clear evidence to support
this assumption is lacking [9].
The aim of this study was to describe the patterns of cannabis
use and the associated benefits reported by patients with
fibromyalgia (FM) who were consumers of this drug. In addition,
the quality of life of FM patients who consumed cannabis was
compared with FM subjects who were not cannabis users.
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Patients
A cross-sectional survey was performed. Participants were
identified through an advertisement from one Rheumatology
Outpatients Unit, 15 associations of FM patients and 1 association
of cannabis consumers, all of them located in the city of Barcelona,
Spain. Recruitment began in August 2005, and the study was
completed in April 2007. Patients were eligible if they were $18
years of age, had been diagnosed with FM according to the
American College of Rheumatology criteria [1], had moderate to
severe symptomatology, and were resistant to pharmacological
treatment. Exclusion criteria were severe illness and history of
abuse or dependence for cannabis or others psychoactive
substances.
Ethics statement
The study was approved by the local Institutional Review Board
(CEIC-IMAS) and all volunteers gave their written informed
consent before inclusion.
Study procedures and evaluation
Patients were divided according their status of therapeutic
cannabis use. Eligibility and exclusion criteria were checked
through an accurate telephone interview. Demographic (age,
gender and employment status) and clinical variables (duration of
FM, number of medical consultations in the last year, associated
symptoms, current pharmacological treatment, comorbid condi-
tions, and alternative and complementary medicines) were also
collected through a structured telephone interview. Patients were
informed that a specific questionnaire to collect information on
medicinal cannabis use will be posted to them as well as visual
analogue scales (VAS) to record perceived benefits with compre-
hensive instructions how to fill them out.
The following variables were recorded: duration of cannabis
use, previous use, cannabis derivative used (hashish or marijuana),
route of administration, amount and frequency of use, supply
source, physician’s acknowledgement about cannabis use and
changes of pharmacological treatment. Symptoms from which
cannabis was used and perceived relief was recorded using 5-point
Likert scale (strong relief, mild relief, not change, slight worsening,
great worsening). Patients were further asked to record the
perceived benefits of cannabis on a range of symptoms (pain,
stiffness, relaxation, drowsiness, well-being) using 100-mm VAS
scales (VAS) before and at 2 hours of cannabis consumptions. The
occurrence and frequency of side effects were indicated based on a
list of symptoms.
In order to compare the quality of life between users and non
users of cannabis, three questionnaires were used:
The 36-item Short Form Health Survey (SF-36) is a self-
administered questionnaire, validated in Spanish, in which eight
dimensions of health-related quality of life are assessed: physical
functioning, role-physical, bodily pain, general health, vitality,
social functioning, role-emotional and mental health. Each scale is
scored using norm-based methods, with higher scores indicating
better health. Scores are aggregated further to produce physical
and mental component summary measures of health status, using
norm-based methods. The subscale scores are standardized and
range from 0 to 100 with higher scores reflecting better health-
related quality of life in the domain being measured [10].
The Fibromyalgia Impact Questionnaire (FIQ) is a self-
administered questionnaire, validated in Spanish to assess
health-related quality of life specifically in patients with fibromy-
algia over the previous week. It consists of VAS and questions
regarding limitations of daily living activities. The total score
ranges from 0 to 80; a higher score indicates a more negative
impact [11].
The Pittsburg Sleep Quality Index (PSQI) is a self-administered
questionnaire, validated in Spanish, to measure the quality and
patterns of sleep over the last month. It consists of 7 components
that sum each other and give a total score range from 0 (no
difficulties) to 21 (severe difficulties) [12].
Statistical analysis
Data obtained from the questionnaires were analysed using the
SPSS software (version 12.0.1). Comparisons were carried out
using Fisher Exact tests for categorical variables and Student t test
for continuous variables. The Mann-Whitney U test was used
when the size of a comparison group was too small to assume
normality. Statistical significance was at the 5% level and all tests
were two sided.
Results
In response to the advertisement, 70 patients contacted the
researchers to inquire about the study and were screened by
telephone. A total of 14 subjects, –6 cannabis users and 8 non-
users–, did not meet the eligibility criteria. Therefore, 56 FM
patients completed the study protocol, 28 of them were cannabis
users (mainly recruited through FM association and cannabis
association) and 28 were non-cannabis users (mainly recruited
through FM associations and the Rheumatology Outpatients Unit
of the hospital).
As shown in Table 1, there were no statistically significant
differences between the cannabis users and non-users groups in
any demographic or clinical variables. The most frequent
comorbid diseases were also balanced between the study groups.
No significant differences were observed for the percentage of
patients with irritable bowel syndrome, chronic fatigue syndrome,
restless legs syndrome, osteoarthritis, Sjo ¨gren’s syndrome, and
hypothyroidism (data not shown in Table 1). With regard to
treatment based on complementary and alternative medicines,
there were no significant differences between groups, neither in
number (cannabis group 64%; non-users group, 75%) or
modalities chosen (data not shown in Table 1).
Patterns of cannabis use
Of the 28 FM patients using cannabis, 11 (40%) reported a
duration of cannabis use of less than one year, 9 (32%) between 1
and 3 years, and 8 (29%) more than 3 years. Only 8 patients in the
cannabis group have used cannabis recreationally before the
medicinal use. Cannabis derivate used in every case was
marijuana. The usual methods of administration were smoking
and eating, and some patients use to combine both methods. Only
smokers were 11%, only eaters were 46% and those using both
methods were 43%. The amount and frequency of cannabis use
were diverse among patients. The most frequent doses were
between 1 and 2 cigarettes each time when patients smoked and 1
spoonful each time when eating. Most of the patients (n=12) used
cannabis daily, while 5 used it 2–4 days per week, 3 used it less
than twice a week and 8 patients used it only occasionally. Related
amount of cannabis used in one day, 12 reported once a day, 11
reported 2–3 times a day and 3 reported more than 3 times a day.
Source of supply of cannabis were from family and friends (n=14),
illicit market (n=7), growing (n=5) and associations (n=2). A
total of 19 patients have informed their doctor about cannabis use,
and reduction of pharmacological treatment was accomplished in
19 (68%) patients as well when they started using cannabis.
Cannabis Use in Patients with Fibromyalgia
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Main symptoms leading to cannabis use and perceived benefits
is shown in Figure 1. Patients used cannabis not only to alleviate
pain but for almost all the symptoms associated to FM, and no one
reported worsening of symptoms following cannabis use. The
proportion of patients who reported strong relief ranged from 81%
for sleep disorders to 14% for headache.
All symptoms assessed by VAS showed statistically significant
improvement following 2 hours of cannabis self-administration
(Figure 2). The mean reduction of pain was 37.1 mm (p,0.001, t-
Test) and of stiffness 40.7 mm (p,0.001). The change from
baseline in VAS relaxation and somnolence scores also signifi-
cantly increased (27.6 mm, p,0.05 and 20.0 mm, p,0.05
respectively). In addition, perception of well-being was significantly
higher as compared with baseline (40.0 mm, p,0.001).
Perceived side effects of cannabis use
At least one side effect was reported by 96% (n=27) of patients.
The most frequent were somnolence (n=18), dry mouth (n=17),
sedation (n=12), dizziness (n=10), high (n=9), tachycardia
(n=8), conjunctival irritation (n=7) and hypotension (n=6).
The frequency most commonly reported were ‘sometimes’ for
somnolence, sedation, dizziness, high, tachycardia and conjuncti-
val irritation, and ‘always’ for dry mouth, sedation and
hypotension. No serious adverse events occurred.
Quality of life
The mental health component summary score of the SF-36
questionnaire was slightly but significantly higher in the cannabis
group (mean (M)=29.66standard deviation (SD)=8.2) than in
the non-users group (M=24.96SD=8.9), p,0,05, t-Test. In the
physical component summary score the differences were non
significant between groups (cannabis group: M=26.296SD=6.7;
non-users group: M=27.346SD=5.8; p=0,53, t-Test).
No differences were found either in the Fibromyalgia Impact
Questionnaire (M=65.56SD=11.9; M=65.56SD=12.8;
p=0.36, t-Test) or in the Pittsburg Sleep Quality Index
(M=14.16SD=3.2; M=14.46SD=3.3; p=0.73, t-Test).
Discussion
This observational study provides information on the patterns of
cannabis use for therapeutic purposes among a group of patients
with FM. Most of them were middle-aged women that did not
respond to current treatment and self-administered marijuana,
devoid of medical advice. Patients referred cannabis use in order
to alleviate pain as well as other manifestations of FM. Significant
relief of pain, stiffness, relaxation, somnolence and perception of
well-being, evaluated by VAS before and 2 hours after cannabis
self-administration was observed.
Table 1. Patient characteristics*.
Cannabis
(n=28)
Control
(n=28) P-values
Age, mean 6 SD 50611.9 5067.7 0.94
a
Female 26 (93) 27 (96) 1.00
b
Employment status 0.89
b
Work disability 10 (36) 10 (36)
Unemployment 6 (21) 5 (18)
Currently working 5 (18) 6 (21)
Illness dismissed 3 (11) 5 (18)
Retired 4 (14) 2 (7)
Disease duration (years),
median (range)
5.0 (1–20) 4.0 (1–14) 0.07
c
Nu of physician visits in last year,
median (range)
6.0 (0–26) 6.0 (0–46) 0.76
c
Associated symptoms
Widespread pain 27 (96) 28 (100) 1.00
b
Tiredness 25 (89) 28 (100) 0.23
b
Morning tiredness 27 (96) 27 (96) 1.00
b
Stiffness 25 (89) 27 (96) 0.61
b
Anxiety 24 (86) 25 (89) 1.00
b
Sleep disturbances 24 (86) 24 (86) 1.00
b
Headaches 22 (79) 20 (71) 0.75
b
Mood disorders 19 (68) 22 (79) 0.54
b
Pharmacological treatment 26 (93) 26 (93) 1.00
b
Analgesic/Anti-inflammatory
drugs
21 (75) 18 (64) 0.56
b
Antidepressants 14 (50) 17 (61) 0.59
b
Anxiolytics 10 (36) 10 (36) 1.00
b
Opioids 6 (21) 11 (39) 0.24
b
Myorelaxants 1 (4) 6 (21) 0.10
b
Hypnotics 5 (18) 8 (29) 0.52
b
*Except where indicated otherwise, values are nu (%);
a: t-test;
b: Fisher test;
c: U Mann-Whitney.
doi:10.1371/journal.pone.0018440.t001
Figure 1. Symptoms and perceived relief reported by FM patients using cannabis. Note: Perceived relief was recorded using 5-point Likert
scale (strong relief, mild relief, not change, slight worsening, great worsening). Black bars: strong relief; grey bars: mild relief; white bars: not change.
doi:10.1371/journal.pone.0018440.g001
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SF-36 questionnaire was slightly but significantly higher in the
cannabis group than in the non-users group, whether these
findings are clinically significant remains unclear.
The external validity of this study can be limited for some
factors. The main limitation is the self-selection bias, mainly
related to the fact that the majority of patients in the cannabis
group were recruited from a cannabis association. It is not known
how these patients are different from the ones recruited from FM
associations or from the rheumatology unit. In addition the
patients included in the study were all responders to cannabis self-
administration. Consequently, characteristics of the patients that
have used cannabis and have not obtained symptoms relief are
unidentified. Others limitations were the small size of the sample
and, the variability of patterns of cannabis use among FM patients.
A previous observational study of patients with chronic pain of
different origins using cannabis has revealed similar results
regarding symptoms relief [13]. Furthermore, significant reduc-
tions in VAS score for pain, FIQ global score and FIQ anxiety
score were also seen in the first randomized controlled trial of 40
FM patients with continued pain despite the use of other
medications treated with nabilone (synthetic cannabinoid agonist)
during 4 weeks [7]. In a recent randomized, equivalency and
crossover trial, nabilone was found to have a greater effect on sleep
than amitriptyline on the ISI (Insomnia Severity Index), and was
marginally better on the restfulness based on the LSEQ (Leeds
Sleep Evaluation Questionnaire) [8]. These results seem to
indicate a possible role of cannabinoids on the treatment of FM,
although it should be confirmed in further clinical trials.
Moreover, according to hypothetical and experimental evi-
dence, a Clinical Endocannabinoid Deficiency has been proposed
to be involved on the pathophysiology of FM and other functional
conditions alleviated by cannabis [9]. The participation of the
endocannabinoid system in multiple physiological functions such
as pain modulation, stress response system, neuroendocrine
regulation and cognitive functions among others, is well known
[5]. Additionally, the innovative psychoneuro-endocrinology-
inmunology (PNEI) studies have shown that chronic pain may
be strongly influenced by dysfunctions of the stress system and,
particularly, the HPA-axis [14]. Studies have shown that the HPA-
axis and the autonomic nervous system is disturbed in patients
with fibromyalgia [3] and, polymorphisms of genes in the
serotoninergic, dopaminergic and catecholaminergic systems
may also play a role in the pathogenesis of FM [15]. Notably,
these polymorphisms all affect the metabolism or transport of
monoamines, compounds that have a critical role in both sensory
processing and the human stress response [16]. Endocannabinoids
and cannabinoid receptors are involved in the responses of animals
to acute, repeated and variable stress [17] and there is good
evidence that the cannabinoid receptors play a major role in
modulating neurotransmitter release such as serotonin and
dopamine among others [18]. However, the endocannabinoid
system and its implication in stress response in humans have not
been so far investigated. Because of many methodological pitfalls
in life stress research, high quality studies of the role of stress in the
etiopathogenesis of unexplained chronic pain syndromes, such as
fibromyalgia, are scarce.
We observe significant improvement of symptoms of FM in
patients using cannabis in this study although there was a
variability of patterns. This information, together with evidence
of clinical trials and emerging knowledge of the endocannabinoid
system and the role of the stress system in the pathopysiology of
FM suggest a new approach to the suffering of these patients.
The present results together with previous evidence seem to
confirm the beneficial effects of cannabinoids on FM symptoms.
Further studies regarding efficacy of cannabinoids in FM as well as
cannabinoid and stress response system involvement in their
pathophysiology are warranted.
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